Artemis Investment Management LLP acquired a new stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 158,000 shares of the biopharmaceutical company’s stock, valued at approximately $8,805,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of BMY. First Trust Advisors LP lifted its stake in shares of Bristol-Myers Squibb by 10.7% in the second quarter. First Trust Advisors LP now owns 433,050 shares of the biopharmaceutical company’s stock worth $24,130,000 after buying an additional 41,892 shares in the last quarter. Toronto Dominion Bank lifted its stake in shares of Bristol-Myers Squibb by 54.0% in the first quarter. Toronto Dominion Bank now owns 464,591 shares of the biopharmaceutical company’s stock worth $25,264,000 after buying an additional 162,884 shares in the last quarter. Mutual of America Capital Management LLC lifted its stake in shares of Bristol-Myers Squibb by 1.9% in the first quarter. Mutual of America Capital Management LLC now owns 201,037 shares of the biopharmaceutical company’s stock worth $10,932,000 after buying an additional 3,833 shares in the last quarter. Dividend Assets Capital LLC purchased a new position in shares of Bristol-Myers Squibb in the second quarter worth about $737,000. Finally, Quantitative Investment Management LLC purchased a new position in shares of Bristol-Myers Squibb in the first quarter worth about $6,150,000. 69.51% of the stock is currently owned by institutional investors and hedge funds.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares in the company, valued at $2,777,820. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.23% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Artemis Investment Management LLP Acquires Shares of 158,000 Bristol-Myers Squibb Company (BMY)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/19/artemis-investment-management-llp-acquires-shares-of-158000-bristol-myers-squibb-company-bmy.html.

Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at $61.32 on Friday. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $66.10. The firm has a market cap of $100,362.44, a PE ratio of 20.72, a price-to-earnings-growth ratio of 2.42 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same quarter in the prior year, the business earned $0.77 earnings per share. Bristol-Myers Squibb’s revenue was up 6.7% on a year-over-year basis. equities research analysts anticipate that Bristol-Myers Squibb Company will post 2.99 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date of this dividend was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 61.42%.

Several equities analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. SunTrust Banks, Inc. raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Credit Suisse Group reissued a “hold” rating and issued a $61.00 price target (up from $58.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Piper Jaffray Companies reissued a “hold” rating and issued a $60.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Finally, BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $64.93.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.